statnews.com·Apr 23, 2026
Sanofi's research priorities are shifting under new CEO Belén Garijo, who may reconsider the company's focus on immunology due to recent disappointing results. Additionally, a gene therapy for deafness is showing promising real-world benefits, while concerns arise over the implications of ultra-cheap telehealth options on patient care.
The article mentions that Sanofi's research priorities are in flux with the arrival of new CEO Belén Garijo, raising questions about whether the company will continue its focus on immunology despite recent lackluster results. This could signal potential shifts in their R&D strategy, which might present opportunities or risks for stakeholders monitoring developments in biotech and pharmaceutical sectors.